Make way for some waves. CVS Health (CVS) and Express Scripts (ESRX) have released their formulary exclusion list for 2017, which details which prescription drugs will not be covered by health plans.
Why do we care? Commercial payors have been showing signs of pushing back against high drugs costs, which is a huge concern for drug companies and their investors. The coverage list determines whether millions of privately insured individuals can easily use an insurance co-payment to buy their prescriptions. If a drug is excluded, it can dramatically hobble sales.
Thus, the formulary exclusion lists can be used as a tool by insurers and PBMs leverage you might say to negotiate with drug makers for better prices. Its also a double edged sword that can cost a PBM customers.
Express Scripts says it will save customers $1.8 billion in 2017 by excluding a list of 85 drugs from its formulary in 2017. It added a handful of new names to the list, including Bristol-Myers Squibb‘s (BMY) arthritis medication Orencia, Eli Lilly‘s (LLY) new psoriasis medication and Valeants (VRX) Zyclara, an actinic keratosis skin cream, while also removing several names, including Pfizer‘s (PFE) arthritis drugs Xeljanz (it is now a preferred alternative follow price negotiations with Express Scripts).
Best Low Price Stocks To Own Right Now: Plains All American Pipeline L.P.(PAA)
- [By ]
The market has pummeled master limited partnerships (MLPs) over the past few years due to the impact the oil market downturn had on their operations and business model. Among the hardest-hit have been oil pipeline MLP Plains All American Pipeline (NYSE:PAA) and gas pipeline giant Energy Transfer Partners (NYSE:ETP), both of which have lost more than half their value over the last three years. That persistent slump comes even though their turnaround strategies are beginning to gain steam. While these companies still have some work to do before they’re back on solid ground, both could deliver significant returns as they complete their plans and the oil market continues rebounding over the next few years. That upside potential makes them compelling options for investors with a higher tolerance for risk.
- [By Matthew DiLallo]
One of the largest projects is the Saddlehorn Pipeline, which Magellan is building with Plains All American Pipeline (NYSE:PAA) and Anadarko Petroleum (NYSE:APC). Both Plains All American Pipeline and Magellan own 40% of the project, which puts their total investment at $230 million apiece. They expect the project to be fully operational early next year, which is noteworthy given its robust first-year economics. Magellan estimates that it will earn eight times EBITDA on the capital deployed, or roughly $28.8 million in annual EBITDA apiece for Magellan and Plains All American Pipeline on their investment.
- [By Dustin Parrett]
We think Plains All American Pipeline L.P. (NYSE: PAA) is one of the best oil stocks to buy this year. In fact, we see a scenario where PAA stock could jump 20% in 2017.
- [By Dustin Parrett]
Plains All American Pipeline (NYSE: PAA) controls 4 million barrels of crude oil and natural gas a day.
And with higher oil prices and fewer restrictions leading to more drilling, PAA’s pipelines will be in demand in 2017.
Best Low Price Stocks To Own Right Now: Credicorp Ltd.(BAP)
- [By Zacks]
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bank of Nova Scotia (The) (NYSE: BNS): Free Stock Analysis Report
Banco Bilbao Viscaya Argentaria S.A. (NYSE: BBVA): Free Stock Analysis Report
Credicorp Ltd. (NYSE: BAP): Free Stock Analysis Report
Bank of N.T. Butterfield & Son Limited (The) (NTB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Best Low Price Stocks To Own Right Now: Preferred Bank(PFBC)
- [By WWW.MONEYSHOW.COM]
Preferred Bank (PFBC) has surged 54% in the past year but still trades at a modest discount to the median S&P 1500 regional bank, based on both trailing earnings and estimated 2017 profits.